³í¹®) Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities ¿¬¼¼´ë ÀÇ°ú´ëÇÐ ÀÇ»ý¸í°úÇкΠ±èÇö¼® ±³¼ö¿Í KIST ÀÌöÁÖ Ã¥ÀÓ¿¬±¸¿ø, »ï¼º¼¿ïº´¿ø ³²µµÇö ±³¼ö ¿¬±¸ÆÀ